Destiny Pharma plc
("Destiny Pharma" or the "Company")
Grant of Share Options
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections, announces that it has granted options over a total of 3,053,532 new ordinary shares of £0.01 each in the Company ("Options") (representing 3.21 per cent. of the Company's issued share capital) to the below named Directors of the Company.
| Name | Position | Performance Options issued Under 2020 LTIP Scheme | Total Options held post issue | Options held as a percentage of issued share capital | Ordinary Shares held | Ordinary Shares held as a percentage of issued share capital
|
| Chris Tovey | Chief Executive Officer | 2,453,532 | 2,453,532 | 2.58% | 40,000* | 0.04% |
| Shaun Claydon | Chief Financial Officer | 300,000 | 1,211,001 | 1.27% | 24,286 | 0.03% |
| William Love | Chief Scientific Officer | 300,000 | 1,259,549 | 1.32% | 6,509,500** | 6.83% |
*10,000 of these Ordinary Shares are held by Chris Tovey and 30,000 are held by Chris Tovey's wife and two daughters
**1,017,700 of these Ordinary Shares are held by William Love and 5,491,800 are held by Carol Love
The above Options granted to the Directors represent awards under the Destiny Pharma plc 2020 Long Term Incentive Plan approved by the Company on 22 December 2020 for EMI and non-tax advantaged options (the "Employee LTIP 2020"). The Options, which represent awards to Shaun Claydon and William Love in relation to the year ended 31 December 2022 and to Chris Tovey pursuant to an agreed equity incentive award on joining the Company, have been granted with a nominal exercise price and will vest subject to the achievement of Total Shareholder Return targets over a three-year performance period. Following the grant of these Options, the Company will have in issue outstanding options representing approximately 11.3 per cent. of its issued share capital.
The Total Shareholder Return metrics will be fully laid out in the Company's report and accounts for the year to 31 December 2023.
For further information, please contact:
Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0) 127 370 4440
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance
Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
Powerscourt Group
Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher Ward
+44 (0) 20 7250 1446
About Destiny Pharma
Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.
For further information on the Company, please visit www.destinypharma.com
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Chris Tovey |
| 2. | Reason for the Notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Destiny Pharma plc |
| b) | LEI | 213800O9WH9Z38EHAC95 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
|
| Identification code | DEST GB00BDHSP575 | |
| b) | Nature of the transaction | Grant of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan. |
| c) | Price(s) and volume(s) | 1 pence exercise price per Ordinary Share 2,453,532 Ordinary Shares |
| d) | Aggregated information: Aggregated volume Price |
See 4c) above
|
| e) | Date of the transaction | 18 October 2023 |
| f) | Place of the transaction | Outside of trading venue |
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Shaun Claydon |
| 2. | Reason for the Notification | |
| a) | Position/status | Chief Financial Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Destiny Pharma plc |
| b) | LEI | 213800O9WH9Z38EHAC95 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan.
|
| Identification code | DEST GB00BDHSP575 | |
| b) | Nature of the transaction | Grant of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan. |
| c) | Price(s) and volume(s) | 1 pence exercise price per Ordinary Share 300,000 Ordinary Shares |
| d) | Aggregated information: Aggregated volume Price |
See 4c) above
|
| e) | Date of the transaction | 18 October 2023 |
| f) | Place of the transaction | Outside of trading venue |
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | William Love |
| 2. | Reason for the Notification | |
| a) | Position/status | Chief Scientific Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Destiny Pharma plc |
| b) | LEI | 213800O9WH9Z38EHAC95 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan.
|
| Identification code | DEST GB00BDHSP575 | |
| b) | Nature of the transaction | Grant of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan. |
| c) | Price(s) and volume(s) | 1 pence exercise price per Ordinary Share 300,000 Ordinary Shares |
| d) | Aggregated information: Aggregated volume Price |
See 4c) above
|
| e) | Date of the transaction | 18 October 2023 |
| f) | Place of the transaction | Outside of trading venue |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.